Dietary phytochemicals in cancer prevention and therapy: A complementary approach with promising perspectives

Nutrition Reviews

Volumn 71, Issue 9, 2013, Pages 585-599

  González Vallinas, Margarita ^a   González Castejón, Marta ^a   Rodríguez Casado, Arantxa ^a   Ramírez de Molina, Ana ^a  

^a IMDEA FOOD INSTITUTE   (Spain)

Author keywords

Cancer; Dietary phytochemicals; Nutrigenomics; Nutritional supplements; Polyphenols; Prevention; Therapy

Indexed keywords

3 INDOLEMETHANOL; ALLYL COMPOUND; BLEOMYCIN; CAMPTOTHECIN; CARNOSOL; CISPLATIN; CURCUMIN; DIALLYL DISULFIDE; DOXORUBICIN; ELLAGIC ACID; ERLOTINIB; FLAVONOID; GEMCITABINE; GENISTEIN; LUTEOLIN; LYCOPENE; ORGANOSULFUR DERIVATIVE; PACLITAXEL; PHYTOSTEROL; PLANT MEDICINAL PRODUCT; POLYPHENOL; QUERCETIN; RESVERATROL; STILBENE; STILBENE DERIVATIVE; SULFORAPHANE; TERPENOID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADRENAL CANCER; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CANCER; BLUEBERRY; BREAST CANCER; CANCER CENTER; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELERY; CITRUS FRUIT; COFFEE; COLORECTAL CANCER; DIET SUPPLEMENTATION; DRUG POTENTIATION; GARLIC; GENOMIC INSTABILITY; GRAPE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; MYCOSIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PARSLEY; PEANUT; PROSTATE CANCER; SOYBEAN; STOMACH CANCER; TEA; THYROID CANCER; UTERINE CERVIX CANCER; VEGETABLE;

EID: 84883449953     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12051     Document Type: Article

References (146)

1. Murray C, Lopez A. Summary: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996.
2. Choi BC, Bonita R, McQueen DV. The need for global risk factor surveillance. J Epidemiol Community Health. 2001;55:370.
3. World Health Organization/Food and Agriculture Organization. Diet, Nutrition and the Prevention of Chronic Diseases. WHO Tech Rep Ser. 2003;916:Available at: http://whqlibdoc.who.int/trs/who_trs_916.pdf. Accessed July 11, 2013.
4. Key TJ, Appleby P, Spencer EA, etal. Cancer incidence in British vegetarians. Br J Cancer. 2009;101:192-197.
5. Richardson MA, Sanders T, Palmer JL, etal. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:25052514.
6. Kim HK, Wilson EG, Choi YH, etal. Metabolomics: a tool for anticancer lead-finding from natural products. Planta Med. 2010;76:1094-1102.
7. Cragg G, Newman D. Nature: a vital source of leads for anticancer drug development. Phytochemistry Rev. 2009;8:313-331.
8. Danaei G, Vander Hoorn S, Lopez AD, etal. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366:1784-1793.
9. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029-1035.
10. Omenn GS, Goodman GE, Thornquist MD, etal. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88:1550-1559.
11. Alberts DS, Hess LM. Fundamentals of Cancer Prevention. New York, Springer Verlag; 2008.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
13. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13:472-482.
14. Chen Y, Huang C, Zhou T, etal. Genistein induction of human sulfotransferases in HepG2 and Caco-2 cells. Basic Clin Pharmacol Toxicol. 2008;103:553-559.
15. Moon DO, Kim MO, Choi YH, etal. Beta-sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. Cancer Lett. 2008;264:181-191.
16. Wang X, Hao MW, Dong K, etal. Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res. 2009;32:1263-1269.
17. Palozza P, Colangelo M, Simone R, etal. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis. 2010;31:1813-1821.
18. Bagli E, Stefaniotou M, Morbidelli L, etal. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res. 2004;64:7936-7946.
19. Huang SC, Ho CT, Lin-Shiau SY, etal. Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. Biochem Pharmacol. 2005;69:221-232.
20. Cheng CW, Shieh PC, Lin YC, etal. Indoleamine 2, 3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem. 2010;58:887-894.
21. Harris GK, Qian Y, Leonard SS, etal. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells. J Nutr. 2006;136:1517-1521.
22. Yao H, Wang H, Zhang Z, etal. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer. 2008;123:1255-1261.
23. He ZY, Shi CB, Wen H, etal. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29:208-213.
24. Maher DM, Bell MC, O'Donnell EA, etal. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog. 2011;50:47-57.
25. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768-780.
26. Ho JW, Leung YK, Chan CP. Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents. 2002;2:209-214.
27. Ferguson LR, Philpott M. Cancer prevention by dietary bioactive components that target the immune response. Curr Cancer Drug Targets. 2007;7:459-464.
28. Issa AY, Volate SR, Wargovich MJ. The role of phytochemicals in inhibition of cancer and inflammation: new directions and perspectives. J Food Compost Anal. 2006;19:405-419.
29. DellaPenna D. Nutritional genomics: manipulating plant micronutrients to improve human health. Science. 1999;285:375-379.
30. Kaput J, Rodriguez RL. Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics. 2004;16:166-177.
31. Simopoulos AP, Ordovas JM. Nutrigenetics and Nutrigenomics, Vol. 93. Basel (Switzerland), S Karger Pub; 2004.
32. Ferguson LR. Nutrigenomics approaches to functional foods. J Am Diet Assoc. 2009;109:452-458.
33. Milner JA, McDonald SS, Anderson DE, etal. Molecular targets for nutrients involved with cancer prevention. Nutr Cancer. 2001;41:1-16.
34. Scalbert A, Andres-Lacueva C, Arita M, etal. Databases on food phytochemicals and their health-promoting effects. J Agric Food Chem. 2011;59:4331-4348.
35. Fraga CG, Galleano M, Verstraeten SV, etal. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med. 2010;31:435-445.
36. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2:270-278.
37. Linseisen J, Rohrmann S. Biomarkers of dietary intake of flavonoids and phenolic acids for studying diet-cancer relationship in humans. Eur J Nutr. 2008;47(Suppl 2):60-68.
38. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res. 2008;52:507-526.
39. Huang W-Y, Cai Y-Z, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. 2009;62:1-20.
40. Tomás-Barberán FA, Clifford MN. Dietary hydroxybenzoic acid derivatives - nature, occurrence and dietary burden. J Sci Food Agric. 2000;80:1024-1032.
41. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancer - a mini review. J Pharm Pharmacol. 2008;60:139-144.
42. Seeram NP, Lee R, Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta. 2004;348:63-68.
43. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem. 2009;20:743-752.
44. Strati A, Papoutsi Z, Lianidou E, etal. Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem. 2009;42:1358-1362.
45. Narayanan BA, Re GG. IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res. 2001;21:359-364.
46. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269:315-325.
47. Androutsopoulos VP, Papakyriakou A, Vourloumis D, etal. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther. 2010;126:9-20.
48. Khan N, Afaq F, Saleem M, etal. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006;66:2500-2505.
49. Shimizu M, Fukutomi Y, Ninomiya M, etal. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 2008;17:3020-3025.
50. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature. 1999;398:381.
51. Ohga N, Hida K, Hida Y, etal. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci. 2009;100:1963-1970.
52. Shimizu M, Shirakami Y, Sakai H, etal. (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol Interact. 2010;185:247-252.
53. Duhon D, Bigelow RL, Coleman DT, etal. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog. 2010;49:739-749.
54. Koh YW, Choi EC, Kang SU, etal. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J Nutr Biochem. 2011;22:1074-1083.
55. Larsen CA, Dashwood RH. (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys. 2010;501:52-57.
56. Milligan SA, Burke P, Coleman DT, etal. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res. 2009;15:4885-4894.
57. Stuart EC, Jarvis RM, Rosengren RJ. In vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells. Oncol Rep. 2010;24:779-785.
58. Wang Q, Li J, Gu J, etal. Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. Acta Biochim Biophys Sin (Shanghai). 2009;41:1018-1026.
59. Tang SN, Singh C, Nall D, etal. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal. 2010;5:14.
60. Banerjee S, Li Y, Wang Z, etal. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008;269:226-242.
61. Pugalendhi P, Manoharan S, Panjamurthy K, etal. Antigenotoxic effect of genistein against 7, 12-dimethylbenz[a]anthracene induced genotoxicity in bone marrow cells of female Wistar rats. Pharmacol Rep. 2009;61:296-303.
62. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2003;54:68-78.
63. Nakamura Y, Yogosawa S, Izutani Y, etal. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer. 2009;8:100.
64. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 2007;57:260-277.
65. Nobert GS, Kraak MM, Crawford S. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches. Bull Cancer. 2006;93:E59-E66.
66. Mai Z, Blackburn GL, Zhou JR. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis. 2007;28:1217-1223.
67. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci. 2004;9:2714-2724.
68. Ju YH, Allred KF, Allred CD, etal. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis. 2006;27:1292-1299.
69. Lammersfeld CA, King J, Walker S, etal. Prevalence, sources, and predictors of soy consumption in breast cancer. Nutr J. 2009;8:2.
70. Lin Y, Shi R, Wang X, etal. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8:634-646.
71. Seelinger G, Merfort I, Wolfle U, etal. Anti-carcinogenic effects of the flavonoid luteolin. Molecules. 2008;13:2628-2651.
72. Verschooten L, Smaers K, Van Kelst S, etal. The flavonoid luteolin increases the resistance of normal, but not malignant keratinocytes, against UVB-induced apoptosis. J Invest Dermatol. 2010;130:2277-2285.
73. Rao PS, Satelli A, Moridani M, etal. Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int J Cancer. 2011;130:2703-2714.
74. Sekiguchi H, Washida K, Murakami A. Suppressive effects of selected food phytochemicals on CD74 expression in NCI-N87 gastric carcinoma cells. J Clin Biochem Nutr. 2008;43:109-117.
75. Yoo DR, Jang YH, Jeon YK, etal. Proteomic identification of anti-cancer proteins in luteolin-treated human hepatoma Huh-7 cells. Cancer Lett. 2009;282:48-54.
76. Okamoto T. Safety of quercetin for clinical application (Review). Int J Mol Med. 2005;16:275-278.
77. Hollman PCH, Arts ICW. Flavonols, flavones and flavanols - nature, occurrence and dietary burden. J Sci Food Agric. 2000;80:1081-1093.
78. Jan AT, Kamli MR, Murtaza I, etal. Dietary flavonoid quercetin and associated health benefits - an overview. Food Rev Intern. 2010;26:302-317.
79. Lam TK, Rotunno M, Lubin JH, etal. Dietary quercetin, quercetin-gene interaction, metabolic gene expression in lung tissue and lung cancer risk. Carcinogenesis. 2010;31:634-642.
80. Gulati N, Laudet B, Zohrabian VM, etal. The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res. 2006;26:1177-1181.
81. Jones DJ, Lamb JH, Verschoyle RD, etal. Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. Br J Cancer. 2004;91:1213-1219.
82. Jung YH, Heo J, Lee YJ, etal. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci. 2010;86:351-357.
83. Psahoulia FH, Drosopoulos KG, Doubravska L, etal. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther. 2007;6:2591-2599.
84. Chen W, Wang X, Zhuang J, etal. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis. 2007;28:2114-2121.
85. Sharma H, Sen S, Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther. 2005;4:949-955.
86. Rimando AM, Suh N. Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med. 2008;74:1635-1643.
87. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila). 2009;2:409-418.
88. Levi F, Pasche C, Lucchini F, etal. Resveratrol and breast cancer risk. Eur J Cancer Prev. 2005;14:139-142.
89. Nguyen AV, Martinez M, Stamos MJ, etal. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res. 2009;1:25-37.
90. Shamim U, Hanif S, Albanyan A, etal. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J Cell Physiol. 2011;227:1493-1500.
91. Choi HK, Yang JW, Kang KW. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Lett. 2006;242:198-206.
92. Fukui M, Yamabe N, Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer. 2010;46:1882-1891.
93. Chan JY, Phoo MS, Clement MV, etal. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther. 2008;7:1305-1312.
94. He X, Wang Y, Zhu J, etal. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 2011;301:168-176.
95. Harikumar KB, Kunnumakkara AB, Sethi G, etal. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer. 2010;127:257-268.
96. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim). 2010;343:489-499.
97. Masuda T, Hidaka K, Shinohara A, etal. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J Agric Food Chem. 1999;47:71-77.
98. Beevers CS, Chen L, Liu L, etal. Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res. 2009;69:1000-1008.
99. Choi H, Chun YS, Kim SW, etal. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol. 2006;70:1664-1671.
100. Herman JG, Stadelman HL, Roselli CE. Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol. 2009;34:1319-1327.
101. Bhattacharyya S, Md Sakib Hossain D, Mohanty S, etal. Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol. 2010;7:306-315.
102. Shukla S, Zaher H, Hartz A, etal. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009;26:480-487.
103. Dance-Barnes ST, Kock ND, Moore JE, etal. Lung tumor promotion by curcumin. Carcinogenesis. 2009;30:1016-1023.
104. Rabi T, Bishayee A. Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat. 2009;115:223-239.
105. Salminen A, Lehtonen M, Suuronen T, etal. Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci. 2008;65:2979-2999.
106. Maiani G, Caston MJ, Catasta G, etal. Carotenoids: actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans. Mol Nutr Food Res. 2009;53(Suppl 2):S194-S218.
107. Tan HL, Thomas-Ahner JM, Grainger EM, etal. Tomato-based food products for prostate cancer prevention: what have we learned? Cancer Metastasis Rev. 2010;29:553-568.
108. van Breemen RB, Pajkovic N. Multitargeted therapy of cancer by lycopene. Cancer Lett. 2008;269:339-351.
109. Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004;22:415-420.
110. Talvas J, Caris-Veyrat C, Guy L, etal. Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target genes of cancer prostatic cells. Am J Clin Nutr. 2010;91:1716-1724.
111. Walfisch S, Walfisch Y, Kirilov E, etal. Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. Eur J Cancer Prev. 2007;16:298-303.
112. Tang Y, Parmakhtiar B, Simoneau AR, etal. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011;13:108-119.
113. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective, Washington DC, World Cancer Research Fund and American Institute for Cancer Research; 2007.
114. Kristal AR, Till C, Platz EA, etal. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2011;20:638-646.
115. Sesso HD, Buring JE, Zhang SM, etal. Dietary and plasma lycopene and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1074-1081.
116. Goodman M, Bostick RM, Ward KC, etal. Lycopene intake and prostate cancer risk: effect modification by plasma antioxidants and the XRCC1 genotype. Nutr Cancer. 2006;55:13-20.
117. Mikhak B, Hunter DJ, Spiegelman D, etal. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis. 2008;29:2335-2340.
118. Johnson JJ. Carnosol: a promising anti-cancer and anti-inflammatory agent. Cancer Lett. 2011;305:1-7.
119. Nabekura T, Yamaki T, Hiroi T, etal. Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol Res. 2010;61:259-263.
120. Bai N, He K, Roller M, etal. Flavonoids and phenolic compounds from Rosmarinus officinalis. J Agric Food Chem. 2010;58:5363-5367.
121. Moriarty RM, Naithani R, Surve B. Organosulfur compounds in cancer chemoprevention. Mini Rev Med Chem. 2007;7:827-838.
122. Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 2008;269:291-304.
123. Cho SD, Li G, Hu H, etal. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer. 2005;52:213-224.
124. Ramirez MC, Singletary K. Regulation of estrogen receptor alpha expression in human breast cancer cells by sulforaphane. J Nutr Biochem. 2009;20:195-201.
125. Gibbs A, Schwartzman J, Deng V, etal. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A. 2009;106:16663-16668.
126. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007;6:1013-1021.
127. Li Y, Zhang T, Korkaya H, etal. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16:2580-2590.
128. Mi L, Hood BL, Stewart NA, etal. Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol. 2011;24:1735-1743.
129. Naumann P, Fortunato F, Zentgraf H, etal. Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. Int J Oncol. 2011;39:101-109.
130. Chen MJ, Tang WY, Hsu CW, etal. Apoptosis induction in primary human colorectal cancer cell lines and retarded tumor growth in SCID mice by sulforaphane. Evid Based Complement Alternat Med. 2012; doi:10.1155/2012/415231.
131. Milner JA. Preclinical perspectives on garlic and cancer. J Nutr. 2006;136(Suppl 3):S827-S831.
132. Ngo SN, Williams DB, Cobiac L, etal. Does garlic reduce risk of colorectal cancer? A systematic review. J Nutr. 2007;137:2264-2269.
133. Ling H, Wen L, Ji XX, etal. Growth inhibitory effect and Chk1-dependent signaling involved in G2/M arrest on human gastric cancer cells induced by diallyl disulfide. Braz J Med Biol Res. 2010;43:271-278.
134. Ling H, Zhang LY, Su Q, etal. Erk is involved in the differentiation induced by diallyl disulfide in the human gastric cancer cell line MGC803. Cell Mol Biol Lett. 2006;11:408-423.
135. Yang JS, Chen GW, Hsia TC, etal. Diallyl disulfide induces apoptosis in human colon cancer cell line (COLO 205) through the induction of reactive oxygen species, endoplasmic reticulum stress, caspases casade and mitochondrial-dependent pathways. Food Chem Toxicol. 2009;47:171-179.
136. Myzak MC, Dashwood RH. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets. 2006;7:443-452.
137. Arunkumar A, Vijayababu MR, Gunadharini N, etal. Induction of apoptosis and histone hyperacetylation by diallyl disulfide in prostate cancer cell line PC-3. Cancer Lett. 2007;251:59-67.
138. Gayathri R, Gunadharini DN, Arunkumar A, etal. Effects of diallyl disulfide (DADS) on expression of apoptosis associated proteins in androgen independent human prostate cancer cells (PC-3). Mol Cell Biochem. 2009;320:197-203.
139. Escurriol V, Cofan M, Moreno-Iribas C, etal. Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort. J Lipid Res. 2010;51:618-624.
140. Bradford PG, Awad AB. Modulation of signal transduction in cancer cells by phytosterols. Biofactors. 2010;36:241-247.
141. Gupta AK, Savopoulos CG, Ahuja J, etal. Role of phytosterols in lipid-lowering: current perspectives. QJM. 2011;104:301-308.
142. Jones PJ, AbuMweis SS. Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr Opin Clin Nutr Metab Care. 2009;12:147-151.
143. Baskar AA, Ignacimuthu S, Paulraj GM, etal. Chemopreventive potential of beta-sitosterol in experimental colon cancer model - an in vitro and in vivo study. BMC Complement Altern Med. 2010;10:24.
144. von Holtz RL, Fink CS, Awad AB. Beta-sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer. 1998;32:8-12.
145. Park C, Moon DO, Ryu CH, etal. Beta-sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis. Acta Pharmacol Sin. 2008;29:341-348.
146. Lampe JW, Chang JL. Interindividual differences in phytochemical metabolism and disposition. Semin Cancer Biol. 2007;17:347-353.